IDH2 and central nervous system cancer: In conclusion, considering that IDH mutations are a foundational event in glioma progression, targeting IDH mutations at an early stage of the disease is crucial to halt disease progression and prevent the acquisition of additional genetic alterations that could reduce the effectiveness of IDH inhibitors [73].